Navigation Links
Abraxis BioScience Presents Results from Pre-Clinical Study That,Demonstrates nab-Rapamycin's Robust Antitumor Properties and,Ability to Target Intracellular Sites Such as the mTOR Pathway

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, presented first-time data from a pre-clinical study evaluating the toxicity and antitumor effect of nab-rapamycin (ABI-009), an albumin-bound mTOR kinase inhibitor, at the 98th American Association for Cancer Research (AACR) Annual Meeting held April 14-18, 2007 in Los Angeles. Results from the pre-clinical study demonstrated that nab-rapamycin was well-tolerated, showed linear pharmacokinetics, and was highly effective against a number of tumor models in vivo. (Abstract #4719; Nanoparticle Albumin-bound (nab) Rapamycin as an Anticancer Agent).

Leveraging Nab Technology with Rapamycin to Target mTOR Pathway

The mammalian target of rapamycin (mTOR) is a cell-signaling protein that regulates the response of tumor cells to nutrients and growth factors, as well as controls tumor blood supply through effects on vascular endothelial growth factor (VEGF). Rapamycin is an mTOR inhibitor. The mTOR pathway is thought to be overactivated in numerous tumors and plays a critical role in cell survival and resistance to chemotherapy. Inhibition of mTOR activity prevents the signaling to important pathways that control cell growth and lead to a lowering of VEGF levels, thus decreasing the ability of tumors to gain their own blood supply (angiogenesis).

The role of mTOR inhibition has led investigators at Abraxis to explore the use of the nanoparticle albumin-bound (nab(TM)) tumor-targeting technology to enhance the deregulation of mTOR signaling. Nab-rapamycin is also intended to address limitations posed by the poor water solubility of rapamycin and may enable higher concentrations of the drug to reach the tumor tissue. Abraxis plans to commence Phase I clinical trials with nab-rapamycin in 2007.

Abraxis continues to explore the role of nab technology for targeting SPARC an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
2. Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
6. IR BioSciences Announces Promising Data from Study of Its Compound Homspera
7. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
8. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
9. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
10. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
11. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
Post Your Comments:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, ... PTN), a biopharmaceutical company developing targeted, receptor-specific peptide ... unmet medical need and commercial potential, today announced ... of 2,050,000 shares of its common stock and ... its common stock.  Funds under the management of ...
(Date:12/24/2014)... Dec. 23, 2014 PuraMed BioScience®, Inc., (OTC ... (OTC) medicinal and healthcare products, announced it received the ... a hemp-based, advanced headache relief product, for planned distribution ... Colorado , Washington State ... With the MigraPure H Advanced headache relief gel formulation ...
(Date:12/24/2014)... , Dec. 23, 2014  Advanced Medical Isotope ... engaged primarily in the development of brachytherapy devices ... today announced that it has filed a ... Drug Administration ("FDA") for marketing clearance for its ... of the U.S. Food, Drug and Cosmetic Act ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Aug. 22, 2011 BioDelivery Sciences International, Inc. (Nasdaq: ... launch and availability of ONSOLIS (fentanyl buccal soluble film) ... (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO) ONSOLIS is approved in ... be marketed as BREAKYL) for the management of breakthrough ...
... the Food and Drug Administration (FDA) approved Seattle Genetics, ... – Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). ... approved for Hodgkin lymphoma patients after failure of a ... ALCL patients after failure of at least one multi-agent ...
Cached Medicine Technology:BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 2BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada 3The Leukemia & Lymphoma Society Available to Comment on FDA Approval of Seattle Genetics' Adcetris, First New Treatment for Hodgkin Lymphoma Since 1977 2
(Date:12/24/2014)... (PRWEB) December 24, 2014 New studies reveal ... to hearing loss related depression (March 6, 2014, JAMA Otolaryngology*). ... gradual hearing loss (about 50 percent according to recent polls) ... effect on how a person feels and relates to the ... overall improvements are also made by way of:, ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... drug which is used in the treatment of colon ... is also prescribed to patients who suffer from advanced ... is a multi-kinase inhibitor and it blocks many enzymes ...
(Date:12/24/2014)... News) -- Hepatitis C infection does not contribute to mental ... Treatment advances have made it possible for people with ... thinking problems, mood swings and other types of mental impairment ... that long-term infections with other viruses -- a common problem ... of the prime suspects has been the hepatitis C virus, ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- A lab technician with ... have been exposed to the Ebola virus in an ... up to a dozen other lab workers are being ... afternoon. The possible exposure occurred Monday when CDC ... of the potentially lethal virus to another CDC lab ...
(Date:12/24/2014)... Dr. Svetlana Gomer, MGS Tewksbury Dental, MGE Management ... US Marines on November 14, 2014 for the MGE ... for Tots Literacy Program. This year’s event raised ... audio books for the Toys for Tots Literacy Program ... represents another major strike in the battle being waged ...
Breaking Medicine News(10 mins):Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 2Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 3Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 4Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 5Health News:Recent Studys Underscore the Fact That One of the Best Gifts to Give This Holiday Season is a Hearing Test 6Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3
... Researchers at the University of Toronto have identified a ... of neurons, which could enhance our understanding of how ... occur. U of T graduate student John Calarco, ... Centre for Cellular and Biomolecular Research, University of Toronto) ...
... mild depression more likely to suffer major episode later, ... Mildly depressed teenagers are more likely to have major ... new study suggests. , In 1983, researchers interviewed 755 ... and eating disorders, disruptive behaviors and substance abuse. , ...
... ... get Vaccinated , ... Washington, DC (Vocus) - The American Pharmacists Association (APhA) is recommending that ... vaccinated against influenza. Currently almost 80,000 pharmacists have been trained to administer immunizations and ...
... , , MINNEAPOLIS, Sept. ... at all 22 Target Clinic locations in Minnesota. The Centers ... against this potentially serious illness. , , ... available daily at Target Clinic locations during Clinic hours, including ...
... - Hard to Treat Diseases (the "Company") (HTDS.PK) ... Hope, has just finished (August 2009) the clinical ... NUTRIPROTEIN) in India. , This biological product is ... CNS in multiple ways, regulating and improving nerve ...
... could do the same, researchers say , FRIDAY, Sept. 4 ... animals may have a mechanism that allows them to jettison ... any age can do the same. , In fact, scientists ... go into deep storage. , "It,s fair to say that ...
Cached Medicine News:Health News:U of T researchers identify protein 2Health News:Depressed Teens Continue to Suffer 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 3Health News:Seasonal Flu Vaccinations Available Now at Target Clinics in Minnesota 2Health News:Seasonal Flu Vaccinations Available Now at Target Clinics in Minnesota 3Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 2Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 3Health News:Young Animals May Be Able to Erase Bad Memories 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: